Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT02879903
Other study ID # CAAE: 53022216.0.0000.5626
Secondary ID
Status Active, not recruiting
Phase Phase 0
First received August 10, 2016
Last updated August 28, 2016
Start date August 2016
Est. completion date December 2016

Study information

Verified date August 2016
Source Universidade Federal Fluminense
Contact n/a
Is FDA regulated No
Health authority Brazil: National Committee of Ethics in Research
Study type Interventional

Clinical Trial Summary

The aims of the present study will be identify 5 types of fimbrial subunit genotype strains in smokers and nonsmokers with periodontitis, before and after periodontal therapy. Third two periodontitis patients will be selected to these study, 16 nonsmokers and 16 smokers. Clinical and microbiological parameters were evaluated at baseline and 3 months after periodontal treatment: Plaque Index, Bleeding On Probe, Probing Depth, Gingival Recession and Clinical Attachment Level. The prevalence of P. gingivalis and fimbrial subunit gene strains will be determined by Polymerase Chain Reaction.


Description:

Porphyromonas gingivalis is one of the most prevalent periodontopathogens present in red complex that is considered to be infectious agent causing several types of periodontal diseases. P. gingivalis has ability to invade gingival epithelial cells and can survive for extended periods of time. Fimbriae have been characterized to be key factors in adhesion, invasion, and colonization. Fimbriae are also responsible for invasion of membrane vesicles into host cells. Long fimbriae (FimA), also known as major fimbriae, are long, peritrichous, filamentous components. They have a role in initial attachment and organization of biofilms, as they act as adhesins that mediate invasion and colonization of host cells contributing to P. gingivalis virulence.

Fimbrillin (FimA; structural subunit protein of fimbriae) is classified into 5 variants (types I to V) based on their nucleotide sequences. P. gingivalis strains possessing type II fimA are correlated with P. gingivalis-positive patients, and its occurrence was significantly increased with the more severe forms of periodontitis. Previous studies evaluated the differences among the prevalence of fimA genotypes and periodontal health status in adults. P. gingivalis was detected in 36.8% of the healthy subjects and in 87.1% periodontitis patients. Among the P. gingivalis-positive healthy adults, the most prevalent fimA type was type I (76.1%), followed by type V (29.7%). In contrast, a majority of the periodontitis patients carried type II fimA organisms (66.1%), followed by type IV (28.9%). These findings indicate that there are both disease-associated and non-disease-associated strains of P. gingivalis, and that their infectious traits influencing periodontal health status could be differentiated based on the clonal variation of fimA genes.

Tobacco consumption is a risk factor for periodontal disease. Several studies have been reported that smoker habit is associated with greater clinical attachment loss, recession and tooth loss and reduced bone height and density. However, controversial report has been discussed about the differences between smokers and non-smokers periodontopathogens. P. gingivalis have been report 52.2% prevalence in non-smokers and 66.7% in smokers (pocket depth 3-5 mm) , and are associated with high levels in sites with periodontitis.

The mechanism that tobacco affects the periodontal tissue is related with nicotine that has been associated with various cellular changes that may contribute to the initiation and subsequent progression of periodontal disease. It is promote local effect like the reduction of the gingival blood flow, what can be due to long-term effects on the inflammatory lesions, higher incidence of gingival recession and others clinical parameters in smokers is correlated with cytotoxic and vasoactive substances present in tobacco, including nicotine, carbon monoxide and reactive oxidant substances and systemic effect is that smoking is responsible for 90% of cases of lung cancer, type deadliest cancer for men and women smokers, as well as being associated with various lung diseases. Furthermore, they promote oxidative stress and alterations in the immunoinflammatory responses, reducing functional activity of leucocytes, macrophages, lymphocytes and other immune cells, impaired wound healing and microbial recognition.

Nonsurgical therapy using scaling and root planning is the most usual periodontal therapy, well-recognized by the improvement in clinical and microbiological parameters. Fewer studies evaluated longitudinal clinical and microbiological status of smokers undergoing periodontal maintenance therapy and controversial results were found with absence of difference in disease progression in comparison with nonsmokers. P. gingivalis has been reduced after periodontal treatment. Previous report related reduction of 93 % to P.gingivalis for non-smokers and 88 % for smokers after periodontal treatment.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 32
Est. completion date December 2016
Est. primary completion date October 2016
Accepts healthy volunteers No
Gender Both
Age group 27 Years to 70 Years
Eligibility Inclusion Criteria:

Clinical diagnosis of chronic periodontitis Consumption of 10 or more cigarettes/day.

Exclusion Criteria:

Diabetes mellitus Osteoporosis Pregnant and lactating females Immune suppressive medication Phenytoin Cyclosporine Calcium channel blockers Immunotherapy or diagnosed as HIV+

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic


Related Conditions & MeSH terms


Intervention

Procedure:
Periodontal treatment
An experienced periodontist will be performed clinical periodontal parameters, including Plaque Index, Bleeding On Probe, Pocket Probing Depth, Gingival Recession, Clinical Attachment Level using a periodontal probe, at six sites per tooth at all teeth, excluding third molars. Quadrant scaling and root planning will be weekly performed on each patient under local anesthesia using periodontal curettes and ultrasonic scalers. The maintenance therapy will be included professional plaque control and Scaling and root planing in recurrent periodontal pockets.
Microbiological collect
Biofilm will be collected with the paper point to analyse presence of Porphyromonas gingivalis fimbrial subunit gene type I, II, III, IV and V.
Questionnaire
Age will be expressed in years Sex -female and male, will be expressed in percentage. Time of cigarette consumption - will be expressed in years

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Universidade Federal Fluminense

References & Publications (4)

Amano A, Kuboniwa M, Nakagawa I, Akiyama S, Morisaki I, Hamada S. Prevalence of specific genotypes of Porphyromonas gingivalis fimA and periodontal health status. J Dent Res. 2000 Sep;79(9):1664-8. — View Citation

Lin X, Wu J, Xie H. Porphyromonas gingivalis minor fimbriae are required for cell-cell interactions. Infect Immun. 2006 Oct;74(10):6011-5. — View Citation

Zeller I, Hutcherson JA, Lamont RJ, Demuth DR, Gumus P, Nizam N, Buduneli N, Scott DA. Altered antigenic profiling and infectivity of Porphyromonas gingivalis in smokers and non-smokers with periodontitis. J Periodontol. 2014 Jun;85(6):837-44. doi: 10.190 — View Citation

Zhao L, Wu YF, Meng S, Yang H, OuYang YL, Zhou XD. Prevalence of fimA genotypes of Porphyromonas gingivalis and periodontal health status in Chinese adults. J Periodontal Res. 2007 Dec;42(6):511-7. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Change from baseline Bleeding on Probe to 3 months Bleeding On Probe will be expressed in percentage per individual to evaluate presence of bleeding on probe. 3 months Yes
Primary Change from Baseline Plaque Index to 3 months Plaque Index will be expressed in percentage per individual to evaluate presence of plaque. 3 months Yes
Primary Change from Baseline Pocket Probing Depth to 3 months Pocket Probing Depth will be evaluated in millimeter. The measure will be performed at six sites per tooth using a periodontal probe. 3 months Yes
Primary Change from Baseline Gingival Recession to 3months Gingival Recession will be evaluated in millimeter. The measure will be performed at six sites per tooth, from cementoenamel junction to gingival margin, using a periodontal probe. 3 months Yes
Primary Change from Baseline Clinical Attachment level to 3 months Clinical Attachment Level will be evaluated in millimeter. The measure will be performed at six sites per tooth, from cementoenamel junction to the end of periodontal pocket, using a periodontal probe. 3 months Yes
Primary Change from Baseline Biofilm to 3 months Pooled biofilms from each site with Probe Depth >5mm will be collected and checked for the presence of fimbrial subunit genotype of Porphyromonas gingivalis I, II, III, IV and V by Polymerase Chain Reaction analysis. The results will be expressed by percentage of frequency of each type of fim A. 3 months Yes
Primary Change from baseline Age to 3 months Age will be expressed in years. 3 months Yes
Primary Change from Baseline Cigarette consumption to 3 months Time of cigarette consumption - will be expressed in years. 3 months Yes
See also
  Status Clinical Trial Phase
Not yet recruiting NCT06400069 - Role of NLRP6 in Chronic Periodontitis
Completed NCT05231096 - Comparison of the Effect of Gingival Massage of Aloe-vera Gel and Sidr Honey on Chronic Periodontitis N/A
Completed NCT03203746 - Gingival Crevicular Fluid Levels of Protein Carbonyl Following the Use of Lycopene in Chronic Periodontitis Phase 1/Phase 2
Active, not recruiting NCT03354338 - Amoxicillin to Prevent Bacteria and Inflammatory Biomarkers After Intensive Periodontal Therapy Phase 2
Completed NCT02516111 - Comparison of Autologous PRF, 1% Alendronate and 1.2% Atorvastatin Gel in Chronic Periodontitis Treatment Phase 2/Phase 3
Completed NCT02174146 - Leptin and Visfatin in Diabetic Patients With Periodontitis Before and After Periodontal Therapy N/A
Terminated NCT02568163 - Influence of Stress on Non Surgical Periodontal Treatment N/A
Completed NCT02430519 - Benefits of Platelet Rich Fibrin In Mandibular Molar Furcation Defects N/A
Completed NCT01233765 - Analysis of Neutrophil Response in Chronic Periodontitis N/A
Completed NCT01438333 - Efficacy of INERSAN in Patients With Chronic Periodontitis as Adjunctive to Full Mouth Disinfection N/A
Completed NCT02218515 - Treatment of Intrabony Periodontal Defects With Enamel Matrix Derivatives and Autogenous Bone Graft Phase 4
Completed NCT02197260 - Antimicrobial Therapy as Adjunct to Periodontal Treatment: Effect of Timing Phase 4
Not yet recruiting NCT03270280 - Comparison of Salivary Interleukin-1β and Matrix Metalloproteinase-8 Levels in Individuals With Chronic Periodontitis Phase 2
Not yet recruiting NCT04026828 - Evaluation of Possible Genes in Periodontal Diseases by Genetic Methods
Completed NCT04643288 - Nanocrystalline Hydroxyapatite Bone Substitute for Treating Periodontal Intrabony Defects N/A
Completed NCT04697199 - The Adjunctive Effect of Probiotics to Non Surgical Treatment of Chronic Periodontitis Phase 1
Completed NCT03039244 - Evaluation of Antimicrobial Photodynamic Therapy as an Adjunct to Periodontal Treatment in Smokers N/A
Completed NCT02898675 - Advantages of Autologous Platelet-Rich Fibrin Membrane on Growth Factor Levels and Periodontal Healing N/A
Completed NCT02851823 - Combined Use of Er:YAG and Nd:YAG Laser N/A
Completed NCT03874390 - Effects of Ozone Therapy on Clinical Parameters and Inflammatory Cytokines in Chronic Periodontitis Patients N/A